^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor) +
    Imjudo (tremelimumab-actl) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

    Excerpt:
    Subject eligibility will be based on PD-L1 expression as determined by a specified IHC assay.
    Trial ID:
    NCT02262741